IBDEI04M ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1478,1,4,0)
 ;;=4^T36.5X5S
 ;;^UTILITY(U,$J,358.3,1478,2)
 ;;=^5049360
 ;;^UTILITY(U,$J,358.3,1479,0)
 ;;=T36.5X5D^^14^156^3
 ;;^UTILITY(U,$J,358.3,1479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1479,1,3,0)
 ;;=3^Adverse effect of aminoglycosides, subsequent encounter
 ;;^UTILITY(U,$J,358.3,1479,1,4,0)
 ;;=4^T36.5X5D
 ;;^UTILITY(U,$J,358.3,1479,2)
 ;;=^5049359
 ;;^UTILITY(U,$J,358.3,1480,0)
 ;;=T45.1X5A^^14^156^5
 ;;^UTILITY(U,$J,358.3,1480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1480,1,3,0)
 ;;=3^Adverse effect of antineoplastic and immunosup drugs, init
 ;;^UTILITY(U,$J,358.3,1480,1,4,0)
 ;;=4^T45.1X5A
 ;;^UTILITY(U,$J,358.3,1480,2)
 ;;=^5051026
 ;;^UTILITY(U,$J,358.3,1481,0)
 ;;=T45.1X5D^^14^156^6
 ;;^UTILITY(U,$J,358.3,1481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1481,1,3,0)
 ;;=3^Adverse effect of antineoplastic and immunosup drugs, subs
 ;;^UTILITY(U,$J,358.3,1481,1,4,0)
 ;;=4^T45.1X5D
 ;;^UTILITY(U,$J,358.3,1481,2)
 ;;=^5051027
 ;;^UTILITY(U,$J,358.3,1482,0)
 ;;=T45.1X5S^^14^156^4
 ;;^UTILITY(U,$J,358.3,1482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1482,1,3,0)
 ;;=3^Adverse effect of antineopl and immunosup drugs, sequela
 ;;^UTILITY(U,$J,358.3,1482,1,4,0)
 ;;=4^T45.1X5S
 ;;^UTILITY(U,$J,358.3,1482,2)
 ;;=^5051028
 ;;^UTILITY(U,$J,358.3,1483,0)
 ;;=T36.8X5A^^14^156^7
 ;;^UTILITY(U,$J,358.3,1483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1483,1,3,0)
 ;;=3^Adverse effect of other systemic antibiotics, init encntr
 ;;^UTILITY(U,$J,358.3,1483,1,4,0)
 ;;=4^T36.8X5A
 ;;^UTILITY(U,$J,358.3,1483,2)
 ;;=^5049412
 ;;^UTILITY(U,$J,358.3,1484,0)
 ;;=T36.8X5D^^14^156^8
 ;;^UTILITY(U,$J,358.3,1484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1484,1,3,0)
 ;;=3^Adverse effect of other systemic antibiotics, subs encntr
 ;;^UTILITY(U,$J,358.3,1484,1,4,0)
 ;;=4^T36.8X5D
 ;;^UTILITY(U,$J,358.3,1484,2)
 ;;=^5049413
 ;;^UTILITY(U,$J,358.3,1485,0)
 ;;=T36.8X5S^^14^156^9
 ;;^UTILITY(U,$J,358.3,1485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1485,1,3,0)
 ;;=3^Adverse effect of other systemic antibiotics, sequela
 ;;^UTILITY(U,$J,358.3,1485,1,4,0)
 ;;=4^T36.8X5S
 ;;^UTILITY(U,$J,358.3,1485,2)
 ;;=^5049414
 ;;^UTILITY(U,$J,358.3,1486,0)
 ;;=T49.6X5A^^14^156^10
 ;;^UTILITY(U,$J,358.3,1486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1486,1,3,0)
 ;;=3^Adverse effect of otorhino drugs and preparations, init
 ;;^UTILITY(U,$J,358.3,1486,1,4,0)
 ;;=4^T49.6X5A
 ;;^UTILITY(U,$J,358.3,1486,2)
 ;;=^5051926
 ;;^UTILITY(U,$J,358.3,1487,0)
 ;;=T49.6X5D^^14^156^11
 ;;^UTILITY(U,$J,358.3,1487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1487,1,3,0)
 ;;=3^Adverse effect of otorhino drugs and preparations, subs
 ;;^UTILITY(U,$J,358.3,1487,1,4,0)
 ;;=4^T49.6X5D
 ;;^UTILITY(U,$J,358.3,1487,2)
 ;;=^5051927
 ;;^UTILITY(U,$J,358.3,1488,0)
 ;;=T49.6X5S^^14^156^12
 ;;^UTILITY(U,$J,358.3,1488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1488,1,3,0)
 ;;=3^Adverse effect of otorhino drugs and preparations, sequela
 ;;^UTILITY(U,$J,358.3,1488,1,4,0)
 ;;=4^T49.6X5S
 ;;^UTILITY(U,$J,358.3,1488,2)
 ;;=^5051928
 ;;^UTILITY(U,$J,358.3,1489,0)
 ;;=T36.95XA^^14^156^13
 ;;^UTILITY(U,$J,358.3,1489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1489,1,3,0)
 ;;=3^Adverse effect of unsp systemic antibiotic, init encntr
 ;;^UTILITY(U,$J,358.3,1489,1,4,0)
 ;;=4^T36.95XA
 ;;^UTILITY(U,$J,358.3,1489,2)
 ;;=^5049430
 ;;^UTILITY(U,$J,358.3,1490,0)
 ;;=T36.95XD^^14^156^14
 ;;^UTILITY(U,$J,358.3,1490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1490,1,3,0)
 ;;=3^Adverse effect of unsp systemic antibiotic, subs encntr
